U.S. biotech firm partners with Japanese company for cancer drug

12/16/2008 | American City Business Journals

Yakult Honsha signed a licensing pact that allows it to market Celsion's ThermoDox, an experimental cancer treatment, in Japan. Celsion, a biotech firm in Columbia, Md., will receive $2.5 million upfront and is entitled to $18 million more once the drug gets clearance from Japanese regulators. Yakult will conduct clinical studies of ThermoDox in Japan.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT